0001104659-23-091054.txt : 20230814
0001104659-23-091054.hdr.sgml : 20230814
20230814095415
ACCESSION NUMBER: 0001104659-23-091054
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230811
FILED AS OF DATE: 20230814
DATE AS OF CHANGE: 20230814
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WEISS MICHAEL S
CENTRAL INDEX KEY: 0001038977
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 231166927
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
4
1
tm2323684-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-08-11
0
0001001316
TG THERAPEUTICS, INC.
TGTX
0001038977
WEISS MICHAEL S
3020 CARRINGTON MILL BLVD, SUITE 475
MORRISVILLE
NC
27560
1
1
0
0
CEO and President
0
COMMON STOCK
2023-08-11
4
P
0
100000
10.13
A
12073021
D
Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.11 to $10.17. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
Includes shares of restricted Common Stock, which vest over various time periods.
/s/ Michael S. Weiss
2023-08-14